loading
Schlusskurs vom Vortag:
$38.05
Offen:
$38.16
24-Stunden-Volumen:
1.40M
Relative Volume:
0.71
Marktkapitalisierung:
$3.38B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-13.95
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+6.55%
1M Leistung:
+4.17%
6M Leistung:
-20.84%
1J Leistung:
-34.38%
1-Tages-Spanne:
Value
$37.02
$39.98
1-Wochen-Bereich:
Value
$35.48
$39.98
52-Wochen-Spanne:
Value
$30.04
$67.88

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Firmenname
Crispr Therapeutics Ag
Name
Telefon
(617) 315-4600
Name
Adresse
BAARERSTRASSE 14, ZUG
Name
Mitarbeiter
393
Name
Twitter
@crisprtx
Name
Nächster Verdiensttermin
2024-12-05
Name
Neueste SEC-Einreichungen
Name
CRSP's Discussions on Twitter

Vergleichen Sie CRSP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRSP
Crispr Therapeutics Ag
39.17 3.21B 170.10M -239.59M -191.20M -2.80
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.65 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.97 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2807 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
86.13 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
485.64 63.90B 14.09B 4.50B 2.96B 39.28

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-14 Hochstufung Evercore ISI In-line → Outperform
2025-02-12 Hochstufung TD Cowen Sell → Hold
2025-02-03 Eingeleitet H.C. Wainwright Buy
2024-08-06 Bestätigt Needham Buy
2024-08-02 Eingeleitet Rodman & Renshaw Buy
2024-06-28 Fortgesetzt Guggenheim Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-11 Herabstufung TD Cowen Market Perform → Underperform
2023-10-17 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-09-27 Eingeleitet Mizuho Buy
2023-08-17 Hochstufung Citigroup Neutral → Buy
2023-05-30 Eingeleitet William Blair Outperform
2023-04-13 Eingeleitet Cantor Fitzgerald Overweight
2023-03-21 Eingeleitet Bernstein Mkt Perform
2023-03-17 Eingeleitet Bryan Garnier Buy
2023-03-07 Eingeleitet Robert W. Baird Neutral
2022-10-11 Eingeleitet Morgan Stanley Underweight
2022-08-09 Herabstufung Barclays Overweight → Equal Weight
2022-06-23 Herabstufung Evercore ISI Outperform → In-line
2022-06-17 Eingeleitet BMO Capital Markets Outperform
2022-04-28 Eingeleitet Credit Suisse Neutral
2021-12-07 Eingeleitet Cowen Market Perform
2021-10-19 Eingeleitet SVB Leerink Outperform
2021-06-14 Hochstufung Citigroup Sell → Neutral
2021-04-21 Hochstufung Jefferies Hold → Buy
2021-03-04 Eingeleitet JMP Securities Mkt Outperform
2020-12-10 Bestätigt Chardan Capital Markets Buy
2020-12-10 Herabstufung Jefferies Buy → Hold
2020-12-10 Bestätigt Needham Buy
2020-12-07 Herabstufung Wells Fargo Overweight → Equal Weight
2020-10-23 Eingeleitet RBC Capital Mkts Sector Perform
2020-10-05 Eingeleitet BofA Securities Buy
2020-07-28 Bestätigt Needham Buy
2020-07-14 Eingeleitet SunTrust Buy
2020-06-15 Bestätigt Canaccord Genuity Buy
2020-03-05 Eingeleitet Stifel Hold
2020-02-03 Herabstufung Evercore ISI Outperform → In-line
2019-11-19 Hochstufung William Blair Mkt Perform → Outperform
2019-11-12 Hochstufung Oppenheimer Perform → Outperform
2019-08-01 Eingeleitet Jefferies Buy
2019-07-26 Eingeleitet Canaccord Genuity Buy
2019-06-10 Eingeleitet ROTH Capital Buy
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-14 Eingeleitet William Blair Mkt Perform
2019-01-28 Herabstufung Goldman Buy → Neutral
2019-01-22 Herabstufung Citigroup Neutral → Sell
Alle ansehen

Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten

pulisher
11:30 AM

CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? - Yahoo

11:30 AM
pulisher
06:59 AM

CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Green Alpha Advisors LLC - MarketBeat

06:59 AM
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Can CRISPR Build On Casgevy's Success With Its In Vivo Pipeline? - Barchart.com

Jun 03, 2025
pulisher
Jun 03, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

The Best Stocks to Invest $1,000 in Right Now - The Motley Fool

Jun 03, 2025
pulisher
Jun 03, 2025

Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) Insider Sells 3,932 Shares of Stock - MarketBeat

Jun 03, 2025
pulisher
Jun 02, 2025

Cas9 Technology Market Projected to Hit $30.4 Billion at a 19.81% CAGR by 2032 - industrytoday.co.uk

Jun 02, 2025
pulisher
Jun 02, 2025

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip - Yahoo Finance

Jun 02, 2025
pulisher
Jun 01, 2025

Trading (CRSP) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 01, 2025
pulisher
Jun 01, 2025

Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 31, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat

May 31, 2025
pulisher
May 31, 2025

Zacks Research Has Positive Outlook for CRSP Q2 Earnings - Defense World

May 31, 2025
pulisher
May 30, 2025

Two Sigma Advisers LP Buys 28,400 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Consensus Target Price from Analysts - MarketBeat

May 30, 2025
pulisher
May 29, 2025

ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRS - GuruFocus

May 29, 2025
pulisher
May 29, 2025

ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRSP Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today - TipRanks

May 29, 2025
pulisher
May 29, 2025

ARK Investment Increases Stake in Crispr Therapeutics (CRSP) | CRSP Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Two Sigma Investments LP Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

May 29, 2025
pulisher
May 28, 2025

Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com

May 28, 2025
pulisher
May 27, 2025

Cathie Wood’s ARK Investment buys 262K shares of Crispr Therapeutics today - TipRanks

May 27, 2025
pulisher
May 27, 2025

Ameriprise Financial Inc. Acquires 18,412 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

May 27, 2025
pulisher
May 27, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

May 27, 2025
pulisher
May 26, 2025

Westwood Holdings Group Inc. Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN

May 26, 2025
pulisher
May 25, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

May 25, 2025
pulisher
May 25, 2025

CRISPR Therapeutics' (CRSP) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat

May 25, 2025
pulisher
May 25, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from HC Wainwright - MarketBeat

May 25, 2025
pulisher
May 24, 2025

CRISPR Therapeutics’ SWOT analysis: gene-editing pioneer’s stock faces pivotal year - Investing.com Nigeria

May 24, 2025
pulisher
May 24, 2025

Q2 EPS Estimate for CRISPR Therapeutics Decreased by Analyst - MarketBeat

May 24, 2025
pulisher
May 24, 2025

Rafferty Asset Management LLC Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Northern Trust Corp Has $10.12 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

May 23, 2025
pulisher
May 23, 2025

Cetera Investment Advisers Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World

May 23, 2025
pulisher
May 23, 2025

Q2 EPS Estimate for CRISPR Therapeutics Lowered by Analyst - Defense World

May 23, 2025
pulisher
May 23, 2025

Transcript : CRISPR Therapeutics AG Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 04 - marketscreener.com

May 23, 2025
pulisher
May 22, 2025

Transcript : CRISPR Therapeutics AG Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 10 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

CRSP July 3rd Options Begin Trading - Nasdaq

May 22, 2025

Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.15
price up icon 0.00%
$575.14
price up icon 0.19%
$301.34
price down icon 0.24%
$36.38
price up icon 0.37%
$4.75
price down icon 2.11%
$478.00
price down icon 0.60%
Kapitalisierung:     |  Volumen (24h):